Abstract: A system for connecting luminaires is provided. The system includes: a first luminaire having an end face having a first slot; a second luminaire having an end face having a second slot; a first elongated joining member having first prongs. The first slot and second slot are in laterally aligned and joined relationship define a first joining member slot having a first wedged end, and the first wedged end is shaped to provide an interference fit with the first prongs wherein advancing the first prongs against the first wedged end forces the first slot and the second slot toward each other to tighten connection between the first luminaire and the second luminaire.

Abstract: A system for connecting luminaires is provided. The system includes: a first luminaire having an end face having a first slot; a second luminaire having an end face having a second slot; a first elongated joining member having first prongs. The first slot and second slot are in laterally aligned and joined relationship define a first joining member slot having a first wedged end, and the first wedged end is shaped to provide an interference fit with the first prongs wherein advancing the first prongs against the first wedged end forces the first slot and the second slot toward each other to tighten connection between the first luminaire and the second luminaire.

Abstract: Disclosed is an apparatus for an optical assembly for an end cap (30) of a lighting fixture (10). The optical assembly includes an outer lens (50) and an inner lens (40) interior of the outer lens (50). The end cap (30) may be coupled to a lighting fixture main housing (12) and configured to enable light from a light source (18) within the main housing (12) to enter the end cap (30), be directed through the inner lens (40), and out the outer lens (50).

Abstract: Disclosed is an apparatus for an optical assembly for an end cap (30) of a lighting fixture (10). The optical assembly includes an outer lens (50) and an inner lens (40) interior of the outer lens (50). The end cap (30) may be coupled to a lighting fixture main housing (12) and configured to enable light from a light source (18) within the main housing (12) to enter the end cap (30), be directed through the inner lens (40), and out the outer lens (50).

Abstract: Novel spatially-defined macrocyclic compounds incorporating peptide bond surrogates are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.

Abstract: Compounds useful in the treatment of autoimmune disease are described by the following general formula: n=0-2 m=0-2 m is not necessarily equal to n; where R1, R3?NH2, F, Cl, C1-C4 alkoxy or phenoxy group, but R1 is not necessarily equal to R3; and R2?H, F, Cl, NH2, or NH—R—XH;

Abstract: Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.

Abstract: Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis. The present invention also relates to reducing drug toxicity which often accompanies traditional therapies for autoimmune diseases. The compounds may also be used to bind antibody in vitro or ex vivo.

Abstract: Novel spatially-defined macrocyclic compounds incorporating peptide bond surrogates are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target, in particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.

Abstract: Novel spatially-defined macrocyclic compounds incorporating peptide bond surrogates are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.

Abstract: Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.

Abstract: The present invention describes new compounds which are useful for binding to the tail or Fc portion of immunoglobulins and so have utility in those applications which require the non-covalent binding interaction of a molecule with the Fc portion of immunoglobulins. Such applications include the detection and purification of immunoglobulins as well as the treatment of certain autoimmune diseases.

Abstract: Compounds useful in the treatment of autoimmune disease are described by the following general formula: n=0-2 m=0-2 m is not necessarily equal to n; where R1, R3?NH2, F, Cl, C1-C4 alkoxy or phenoxy group, but R1 is not necessarily equal to R3; and R2?H, F, Cl, NH2, or NH—R—XH; X?CH2,NH, O, or S.

Abstract: Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.

Abstract: Compounds containing two mono- or disubstituted triazine rings covalently linked by an organic linker, but not linked directly to each other, may be used to treat autoimmune diseases. Autoimmune diseases which are amenable to treatment with compounds of this invention include rheumatoid arthritis, systemic lupus erythematosus (SLE), idiopathic (immune) thrombocytopenia (ITP), glomerulonephritis and vasculitis. The present invention also relates to reducing drug toxicity which often accompanies traditional therapies for autoimmune diseases. The compounds may also be used to bind antibody in vitro or ex vivo.